Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
08 11 2023
Historique:
revised: 04 09 2023
received: 04 04 2023
accepted: 07 09 2023
medline: 9 11 2023
pubmed: 2 10 2023
entrez: 2 10 2023
Statut: ppublish

Résumé

NK-cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by the interaction of the inhibitory receptor NKG2A with the non-classical MHC-I molecules HLA-E in humans or Qa-1

Identifiants

pubmed: 37782273
doi: 10.15252/emmm.202317804
pmc: PMC10630884
doi:

Substances chimiques

Antibodies, Monoclonal 0
Histocompatibility Antigens Class I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17804

Informations de copyright

© 2023 The Authors. Published under the terms of the CC BY 4.0 license.

Références

EMBO Mol Med. 2023 Nov 8;15(11):e17804
pubmed: 37782273
Cancer Cell. 2019 Dec 9;36(6):613-629.e7
pubmed: 31761658
J Exp Med. 1998 Nov 16;188(10):1841-8
pubmed: 9815261
Cancer Cell. 2022 Jun 13;40(6):569-574
pubmed: 35487216
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
J Transl Med. 2023 Mar 2;21(1):162
pubmed: 36864446
Immunity. 2003 Oct;19(4):561-9
pubmed: 14563320
Nat Rev Clin Oncol. 2021 Feb;18(2):85-100
pubmed: 32934330
Front Immunol. 2020 Feb 11;11:7
pubmed: 32117218
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Nat Biotechnol. 2023 Sep;41(9):1296-1306
pubmed: 36635380
Oncoimmunology. 2018 May 10;7(8):e1461305
pubmed: 30221057
Cancer Discov. 2014 May;4(5):522-6
pubmed: 24795012
Clin Cancer Res. 2019 Oct 15;25(20):6052-6060
pubmed: 31308062
Trends Immunol. 2022 Nov;43(11):932-946
pubmed: 36306739
BMC Neurol. 2020 Feb 17;20(1):59
pubmed: 32066399
Blood. 2009 Jun 25;113(26):6593-602
pubmed: 19406986
Blood. 2004 Dec 1;104(12):3664-71
pubmed: 15304389
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
pubmed: 9560253
Eur J Cancer. 2021 Oct 9;158:17-26
pubmed: 34638090
Curr Opin Immunol. 2017 Apr;45:73-81
pubmed: 28236750
Scand J Immunol. 2002 Mar;55(3):221-8
pubmed: 11940227
J Cancer Res Clin Oncol. 2023 Aug;149(9):5705-5715
pubmed: 36547689
J Clin Oncol. 2022 Oct 10;40(29):3383-3393
pubmed: 35452273
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
J Hematol Oncol. 2022 Nov 8;15(1):164
pubmed: 36348457
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Blood. 2016 Mar 3;127(9):1202-5
pubmed: 26738538
Semin Immunol. 2014 Apr;26(2):173-9
pubmed: 24613727
Cancer Res. 2013 Jan 1;73(1):139-49
pubmed: 23149919
Semin Immunol. 2023 Jan;65:101706
pubmed: 36542944
J Immunother Cancer. 2019 Oct 17;7(1):263
pubmed: 31623687
J Exp Med. 1999 Dec 20;190(12):1801-12
pubmed: 10601355
Mol Cancer Res. 2021 Jun;19(6):1076-1084
pubmed: 33674442
J Immunol. 2006 Nov 1;177(9):5759-60
pubmed: 17056497
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
Nat Rev Immunol. 2023 Feb;23(2):90-105
pubmed: 35637393
Methods Mol Biol. 2016;1441:167-74
pubmed: 27177665
Cell Rep Med. 2023 Mar 17;:100978
pubmed: 36933554
Clin Cancer Res. 2020 Nov 1;26(21):5549-5556
pubmed: 32409305
Cancer Sci. 2004 Jan;95(1):98-103
pubmed: 14720334
J Immunol. 2022 Aug 1;209(3):629-640
pubmed: 35840162
Methods Enzymol. 2020;631:257-275
pubmed: 31948551
J Immunol. 2005 Mar 1;174(5):2878-84
pubmed: 15728498
JCI Insight. 2019 Jun 18;5:
pubmed: 31211693
Cancer Sci. 2020 Aug;111(8):3057-3070
pubmed: 32495519
Nat Rev Clin Oncol. 2021 Sep;18(9):558-576
pubmed: 34006998
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217765
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32253221
J Exp Med. 2012 Sep 24;209(10):1869-82
pubmed: 22927549
J Immunol. 1998 May 15;160(10):4951-60
pubmed: 9590243
J Immunother. 2008 Jun;31(5):458-65
pubmed: 18463539
Mol Immunol. 2022 Apr;144:58-70
pubmed: 35203022
Int Rev Cell Mol Biol. 2022;370:65-122
pubmed: 35798507
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Adv Exp Med Biol. 2017;1036:65-79
pubmed: 29275465

Auteurs

Ignacio Melero (I)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Departments of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain.

Maria C Ochoa (MC)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Carmen Molina (C)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Sandra Sanchez-Gregorio (S)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Saray Garasa (S)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Carlos Luri-Rey (C)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Sandra Hervas-Stubbs (S)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Noelia Casares (N)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Edurne Elizalde (E)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Gabriel Gomis (G)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Assunta Cirella (A)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

Pedro Berraondo (P)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Alvaro Teijeira (A)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Maite Alvarez (M)

Program for Immunology and Immunotherapy, CIMA, Universidad de Navarra, Pamplona, Spain.
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Cell Therapy, Stem Cells and Tissue Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH